Current and future treatment options for polycythemia vera.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Polycythemia vera (PV) is a myeloproliferative neoplasm defined by increased red blood cell mass.
• PV patients experience significant symptom burden and high risk of vascular/thrombotic complications.
• Current treatments, including phlebotomy and cytoreductive agents, have limitations in long-term efficacy and tolerability.

Purpose of the Study:

• To review the current treatment landscape for polycythemia vera.
• To discuss emerging targeted therapies, specifically JAK inhibitors, for PV management.
• To highlight unmet needs and future directions in PV therapy.

Main Methods:

• Review of current literature on polycythemia vera treatments.
• Analysis of recent clinical trial data for JAK inhibitors in PV.
• Discussion of established and investigational therapeutic strategies.

Main Results:

• Conventional therapies like phlebotomy and hydroxyurea are standard but have limitations.
• Janus kinase 2 (JAK2) mutations are key drivers in PV pathogenesis.
• Early clinical trial results for JAK inhibitors in PV are now available, indicating potential new treatment avenues.

Conclusions:

• Targeted therapies, particularly JAK inhibitors, represent a significant advancement in PV treatment.
• Further research and clinical trials are needed to optimize JAK inhibitor use and evaluate long-term outcomes.
• Addressing symptom burden and improving quality of life remain critical goals in PV management.